Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

The role of hepatocyte nuclear factor 1β in disease and development.

El-Khairi R, Vallier L.

Diabetes Obes Metab. 2016 Sep;18 Suppl 1:23-32. doi: 10.1111/dom.12715. Review.

PMID:
27615128
2.

Feasibility of overnight closed-loop therapy in young children with type 1 diabetes aged 3-6 years: comparison between diluted and standard insulin strength.

Elleri D, Allen JM, Tauschmann M, El-Khairi R, Benitez-Aguirre P, Acerini CL, Dunger DB, Hovorka R.

BMJ Open Diabetes Res Care. 2014 Dec 11;2(1):e000040. doi: 10.1136/bmjdrc-2014-000040. eCollection 2014.

3.

Overnight closed-loop insulin delivery in young people with type 1 diabetes: a free-living, randomized clinical trial.

Hovorka R, Elleri D, Thabit H, Allen JM, Leelarathna L, El-Khairi R, Kumareswaran K, Caldwell K, Calhoun P, Kollman C, Murphy HR, Acerini CL, Wilinska ME, Nodale M, Dunger DB.

Diabetes Care. 2014;37(5):1204-11. doi: 10.2337/dc13-2644.

4.

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, Broedl UC; EMPA-REG MONO trial investigators.

Lancet Diabetes Endocrinol. 2013 Nov;1(3):208-19. doi: 10.1016/S2213-8587(13)70084-6. Epub 2013 Sep 9.

PMID:
24622369
5.

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.

Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S; Dapagliflozin 006 Study Group.

Diabetes Obes Metab. 2014 Feb;16(2):124-36. doi: 10.1111/dom.12187. Epub 2013 Aug 29.

PMID:
23911013
6.

Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients.

Hartman ML, Xu R, Crowe BJ, Robison LL, Erfurth EM, Kleinberg DL, Zimmermann AG, Woodmansee WW, Cutler GB Jr, Chipman JJ, Melmed S; International HypoCCS Advisory Board.

J Clin Endocrinol Metab. 2013 Mar;98(3):980-8. doi: 10.1210/jc.2012-2684. Epub 2013 Jan 23.

7.

Steroidogenic factor-1 and human disease.

El-Khairi R, Achermann JC.

Semin Reprod Med. 2012 Oct;30(5):374-81. doi: 10.1055/s-0032-1324720. Epub 2012 Oct 8. Review.

8.

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S; Dapagliflozin 006 Study Group.

Ann Intern Med. 2012 Mar 20;156(6):405-15. doi: 10.7326/0003-4819-156-6-201203200-00003.

PMID:
22431673
9.

Analysis of LIN28A in early human ovary development and as a candidate gene for primary ovarian insufficiency.

El-Khairi R, Parnaik R, Duncan AJ, Lin L, Gerrelli D, Dattani MT, Conway GS, Achermann JC.

Mol Cell Endocrinol. 2012 Apr 4;351(2):264-8. doi: 10.1016/j.mce.2011.12.016. Epub 2012 Jan 3.

10.

Role of DAX-1 (NR0B1) and steroidogenic factor-1 (NR5A1) in human adrenal function.

El-Khairi R, Martinez-Aguayo A, Ferraz-de-Souza B, Lin L, Achermann JC.

Endocr Dev. 2011;20:38-46. doi: 10.1159/000321213. Epub 2010 Dec 16. Review.

PMID:
21164257
11.

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators.

N Engl J Med. 2009 Nov 19;361(21):2019-32. doi: 10.1056/NEJMoa0907845. Epub 2009 Oct 30.

12.

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu Z, Allen E, Chen R; CV181-039 Investigators.

Diabetes Obes Metab. 2009 Jun;11(6):611-22. doi: 10.1111/j.1463-1326.2009.01056.x.

PMID:
19515181
13.

Occurrence of impaired fasting glucose in GH-deficient adults receiving GH replacement compared with untreated subjects.

Woodmansee WW, Hartman ML, Lamberts SW, Zagar AJ, Clemmons DR; International HypoCCS Advisory Board.

Clin Endocrinol (Oxf). 2010 Jan;72(1):59-69. doi: 10.1111/j.1365-2265.2009.03612.x. Epub 2009 May 4.

PMID:
19438908
14.

The renin-angiotensin-aldosterone system and hypertension in primary hyperparathyroidism.

Ganguly A, Weinberger MH, Passmore JM, Caras JA, Khairi RM, Grim CE, Edmonson J, Johnston CC.

Metabolism. 1982 Jun;31(6):595-600.

PMID:
7043184
15.

Effects of ethane-1 hydroxy-1, 1-diphosphonate (5 mg/kg/day dose) on quantitative bone histology in Paget's disease of bone.

Alexandre C, Meunier PJ, Edouard C, Khairi RA, Johnston CC.

Metab Bone Dis Relat Res. 1981;3(4-5):309-15.

PMID:
6820112
16.

The measurement of rates of mineral loss with aging.

Smith DM, Norton JA Jr, Khairi R, Johnston CC Jr.

J Lab Clin Med. 1976 May;87(5):882-92.

PMID:
1270894
17.

Demonstration of a diurnal variation in serum parathyroid hormone in primary and secondary hyperparathyroidism.

Sinha TK, Miller S, Feming J, Khairi R, Edmondson J, Johnston CC Jr, Bell NH.

J Clin Endocrinol Metab. 1975 Dec;41(06):1009-13.

PMID:
1239461

Supplemental Content

Loading ...
Support Center